A PHASE 1 STUDY OF [225AC]-FPI-2059 IN ADULT PARTICIPANTS WITH NTSR1-EXPRESSING ADVANCED, METASTATIC AND/OR RECURRENT SOLID TUMOURS

Registry ID

FPI-2059-101

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

FUSION PHARMACEUTICALS INC.

Last update

2022-08-19

Conditions

• METASTATIC SOLID TUMOURS

Related clinical trials

• AN OPEN-LABEL, PHASE I/II FIRST IN HUMAN, DOSE ESCALATION, OPTIMISATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND ANTI-TUMOR ACTIVITY OF IPN01203 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON OR AFTER IMMUNE CHECKPOINT INHIBITOR THERAPIES
• A PHASE 1B/2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK5764227 ALONE AND IN COMBINATION IN PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED UNRESECTABLE OR METASTATIC GASTROINTESTINAL SOLID TUMORS
• A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MK-4700 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
• A PHASE 2 OPEN-LABEL BASKET STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED REVERSIBLE TYROSINE KINASE INHIBITOR BAY 2927088 IN PARTICIPANTS WITH METASTATIC OR UNRESECTABLE SOLID TUMORS WITH HER2-ACTIVATING MUTATIONS
• AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7296682 IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
• A PHASE IA/IB DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC 6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION

View on source registry